Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IFRX InflaRx	$0.81 +4.9%	$1.27	$0.71 ▼ $2.82	$54.24M	1.29	285,048 shs	302,522 shs
IPSC Century Therapeutics	$0.58 -1.6%	$0.54	$0.34 ▼ $3.29	$50.15M	1.77	527,351 shs	125,469 shs
NKGN NKGen Biotech	$0.27 -5.7%	$0.23	$0.10 ▼ $1.37	$12.19M	1.2	1.57 million shs	143,659 shs
VTVT vTv Therapeutics	$15.65 -0.4%	$19.07	$12.12 ▼ $26.99	$49.94M	0.59	23,179 shs	879 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IFRX InflaRx	-1.29%	-8.35%	-53.62%	-39.85%	-49.01%
IPSC Century Therapeutics	+1.93%	-6.87%	+5.57%	+1.41%	-81.23%
NKGN NKGen Biotech	-6.02%	-14.08%	-17.81%	+49.20%	-77.71%
VTVT vTv Therapeutics	-1.42%	-7.39%	-25.51%	-14.21%	-25.40%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
IFRX InflaRx	3.3965 of 5 stars	4.5	3.0	2.2	1.7	0.6
IPSC Century Therapeutics	2.4714 of 5 stars	3.5	4.0	0.9	1.7	0.6
NKGN NKGen Biotech	0.8228 of 5 stars	0.0	5.0	0.6	2.5	0.0
VTVT vTv Therapeutics	1.6845 of 5 stars	3.5	3.0	2.0	0.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IFRX InflaRx	3.00	Buy	$6.60	716.83% Upside
IPSC Century Therapeutics	3.00	Buy	$4.20	621.65% Upside
NKGN NKGen Biotech	0.00	N/A	N/A	N/A
VTVT vTv Therapeutics	3.00	Buy	$35.50	126.78% Upside

Current Analyst Ratings Breakdown

Latest NKGN, IFRX, VTVT, and IPSC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/29/2025	IFRX InflaRx	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Outperform	$2.00
5/29/2025	IFRX InflaRx	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$6.00 ➝ $3.00
5/16/2025	IPSC Century Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$7.00 ➝ $6.00
5/8/2025	IFRX InflaRx	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$6.00
4/29/2025	IFRX InflaRx	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$10.00
4/9/2025	VTVT vTv Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$36.00
4/3/2025	IPSC Century Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$5.00 ➝ $2.00
3/28/2025	IPSC Century Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
3/26/2025	IFRX InflaRx	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$7.00 ➝ $10.00
3/24/2025	IPSC Century Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$11.00 ➝ $7.00
3/21/2025	IFRX InflaRx	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00 ➝ $8.00

(Data available from 6/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IFRX InflaRx	$129.75K	418.05	N/A	N/A	$1.13 per share	0.72
IPSC Century Therapeutics	$6.59M	7.61	N/A	N/A	$1.90 per share	0.31
NKGN NKGen Biotech	$80K	152.32	N/A	N/A	($2.68) per share	-0.10
VTVT vTv Therapeutics	$1.02M	48.96	N/A	N/A	$4.48 per share	3.49

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IFRX InflaRx	-$49.85M	-$0.82	N/A	N/A	N/A	-33,362.70%	-64.17%	-53.39%	8/6/2025 (Estimated)
IPSC Century Therapeutics	-$126.57M	-$0.29	N/A	N/A	N/A	-19.10%	-10.71%	-5.96%	8/14/2025 (Estimated)
NKGN NKGen Biotech	-$82.94M	-$2.45	N/A	∞	N/A	N/A	N/A	-479.36%	N/A
VTVT vTv Therapeutics	-$18.46M	-$3.01	N/A	∞	N/A	N/A	-121.46%	-46.75%	8/6/2025 (Estimated)

Latest NKGN, IFRX, VTVT, and IPSC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	IPSC Century Therapeutics	-$0.31	$0.89	+$1.20	$0.89	$45.52 million	$109.16 million
5/15/2025	Q1 2025	VTVT vTv Therapeutics	-$0.73	-$0.77	-$0.04	-$0.77	N/A	N/A
5/7/2025	Q1 2025	IFRX InflaRx	-$0.18	-$0.14	+$0.04	-$0.14	$0.03 million	$0.03 million
3/20/2025	Q4 2024	IFRX InflaRx	-$0.27	-$0.09	+$0.18	-$0.09	$0.13 million	N/A
3/20/2025	Q4 2024	VTVT vTv Therapeutics	-$0.87	-$0.55	+$0.32	-$0.55	N/A	$0.02 million
3/19/2025	Q4 2024	IPSC Century Therapeutics	-$0.45	-$0.43	+$0.02	-$0.43	$0.67 million	$4.18 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
IFRX InflaRx	N/A	N/A	N/A	N/A	N/A
IPSC Century Therapeutics	N/A	N/A	N/A	N/A	N/A
NKGN NKGen Biotech	N/A	N/A	N/A	N/A	N/A
VTVT vTv Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IFRX InflaRx	N/A	5.31	4.61
IPSC Century Therapeutics	N/A	10.39	10.39
NKGN NKGen Biotech	N/A	0.02	0.02
VTVT vTv Therapeutics	N/A	6.69	6.69

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IFRX InflaRx	42.39%
IPSC Century Therapeutics	50.20%
NKGN NKGen Biotech	76.17%
VTVT vTv Therapeutics	17.51%

Insider Ownership

Company	Insider Ownership
IFRX InflaRx	16.30%
IPSC Century Therapeutics	5.00%
NKGN NKGen Biotech	10.36%
VTVT vTv Therapeutics	1.34%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IFRX InflaRx	60	67.13 million	56.19 million	Optionable
IPSC Century Therapeutics	170	86.16 million	81.85 million	Optionable
NKGN NKGen Biotech	N/A	44.95 million	40.29 million	Not Optionable
VTVT vTv Therapeutics	9	3.19 million	3.15 million	Not Optionable

NKGN, IFRX, VTVT, and IPSC Headlines

Recent News About These Companies

vTv Therapeutics to Participate in the H.C. Wainwright “HCW@Home” Series

June 11, 2025 | globenewswire.com

vTv Therapeutics (NASDAQ:VTVT) Stock Passes Below 50 Day Moving Average - Time to Sell?

June 10, 2025 | marketbeat.com

vTv Therapeutics Inc. (NASDAQ:VTVT) Short Interest Down 24.1% in May

June 2, 2025 | marketbeat.com

vTv Therapeutics (NASDAQ:VTVT) Stock Crosses Above Fifty Day Moving Average - Here's Why

May 26, 2025 | marketbeat.com

vTv resumes Phase III oral T1D drug study

May 21, 2025 | thepharmaletter.com

vTv Therapeutics Appoints Michael Tung, M.D., MBA as Executive Vice President and Chief Financial Officer

May 19, 2025 | quiverquant.com

vTv Therapeutics Appoints Michael Tung, M.D., MBA, to Chief Financial Officer as Company Reinitiates Phase 3 Trial of Oral T1D Adjunctive Therapy to Insulin

May 19, 2025 | globenewswire.com

vTv Therapeutics (NASDAQ:VTVT) Stock Passes Above 50-Day Moving Average - Here's Why

May 18, 2025 | marketbeat.com

Analysts Offer Insights on Healthcare Companies: vTv Therapeutics (VTVT) and Precision BioSciences (DTIL)

May 17, 2025 | theglobeandmail.com

vTv Therapeutics Announces 2025 First Quarter Financial Results and Provides Corporate Update

May 15, 2025 | globenewswire.com

vTv Therapeutics Announces Reinitiation of Screening in CATT1 Phase 3 Trial Evaluating Potential First-in-Class Liver-Selective Glucokinase Activator Cadisegliatin for Type 1 Diabetes

May 15, 2025 | globenewswire.com

vTv Therapeutics Appoints Barry Brown as Interim CFO

April 11, 2025 | tipranks.com

vTv Therapeutics initiated with a Buy at H.C. Wainwright

April 9, 2025 | markets.businessinsider.com

HC Wainwright & Co. Initiates Coverage of vTv Therapeutics (VTVT) with Buy Recommendation

April 9, 2025 | msn.com

vTv Therapeutics cleared to resume clinical trial of diabetes therapy

March 26, 2025 | ncbiotech.org

vTv Therapeutics reports Q4 EPS (55c) vs ($1.67) last year

March 21, 2025 | markets.businessinsider.com

vTv Therapeutics Announces 2024 Fourth Quarter and Full Year Financial Results and Provides Corporate Update

March 20, 2025 | globenewswire.com

vTv Therapeutics Inc.: vTv Therapeutics Announces FDA has Lifted Clinical Hold on Cadisegliatin Program for Diabetes

March 18, 2025 | finanznachrichten.de

Alliance Global says clinical hold lift ‘de-risking’ event for vTv Therapeutics

March 18, 2025 | markets.businessinsider.com

vTv Therapeutics says FDA has lifted clinical hold on cadisegliatin program

March 17, 2025 | markets.businessinsider.com

vTv Therapeutics stock surges on FDA update

March 17, 2025 | au.investing.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NKGN, IFRX, VTVT, and IPSC Company Descriptions

InflaRx NASDAQ:IFRX

$0.81 +0.04 (+4.95%)

As of 02:24 PM Eastern

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases; and Gohibic (vilobelimab) for the treatment of COVID-19 and broader ARDS. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.

Century Therapeutics NASDAQ:IPSC

$0.58 -0.01 (-1.56%)

As of 02:26 PM Eastern

Century Therapeutics, Inc., a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-107, a Nectin-4 CAR-iT targeted product candidate for Nectin-4 positive solid tumors. In addition, it has a strategic collaboration with Bristol-Myers Squibb Company to develop and commercialize up to four iNK or iT programs, including CNTY-104, a multi-specific collaboration program targeting acute myeloid leukemia; and CNTY-106, a multi-specific collaboration program for multiple myeloma. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.

NKGen Biotech NYSE:NKGN

$0.27 -0.02 (-5.70%)

As of 02:08 PM Eastern

NKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. It develops SNK01, an autologous NK cell therapy; and SNK02, an allogeneic NK cell therapy, which are in Phase 1 clinical trials. The company was founded in 2017 and is based in Santa Ana, California.

vTv Therapeutics NASDAQ:VTVT

$15.65 -0.07 (-0.42%)

As of 02:20 PM Eastern

vTv Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes. It is also developing HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 inhibitor, which is in Phase III trial for the treatment of psoriasis, COPD, and atopic dermatitis, as well as TTP-RA, a RAGE antagonist for type 1 diabetes prevention. In addition, the company's other programs include HPP3033, a non-electrophilic therapeutic approach to activating the nuclear factor erythroid 2related factor 2 (Nrf2) pathway for the treatment of chronic diseases associated with oxidative stress; and Azeliragon, a RAGE antagonist for inflammatory lung diseases, including severe COVID-19, as well as for glioblastoma, other cancers, and cancer treatment-related conditions. vTv Therapeutics Inc. has license agreements with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593 for therapeutic, prophylactic, and diagnostic application; and Anteris Bio, Inc. to develop and commercialize HPP971, a Nrf2 activator, as well as with Cantex Pharmaceuticals, Inc.; Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; and Novo Nordisk A/S. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time